3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
6
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Influenza, Human
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spondylitis, Ankylosing
1
Sarcoma
1
Recurrence
1
Psoriasis
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Medullary cystic kidney disease 1
1
Lung Neoplasms
1
Glioblastoma
1
Epstein-Barr Virus Infections
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Crohn Disease
1
Condylomata Acuminata
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
Rituximab
57
Cyclophosphamide
42
fludarabine phosphate
29
Peripheral Blood Stem Cell Transplantation
29
Mycophenolic Acid
22
Dexamethasone
21
Tacrolimus
20
Whole-Body Irradiation
18
Bortezomib
18
Cyclosporine
15
Busulfan
13
ibrutinib
12
Methotrexate
12
Melphalan
12
Radiotherapy
11
Etoposide
11
Antilymphocyte Serum
10
zanubrutinib
9
Calcium Dobesilate
9
venetoclax
7
Sirolimus
7
idelalisib
6
Prednisone
6
Lenalidomide
6
Filgrastim
6
Doxorubicin
6
Cyclosporins
6
Bendamustine Hydrochloride
6
Alemtuzumab
6
sargramostim
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Waldenstrom Macroglobulinemia
×
Vaccines
×
Clear all
NCT02566265
2019-01-30
SHIVERING 2
Yale University
Phase 2
Completed
122 enrolled
10 charts